Imosec M

(Imosec M hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. (Imosec M hydrochloride) is also indicated for reducing the volume of discharge from ileostomies.

Treating the symptoms of diarrhea plus bloating, pressure, and cramps from gas.

Imosec M is an antidiarrheal and antiflatulent combination. It works by slowing the movement of bowel contents. It also breaks up gas bubbles to make gas easier to eliminate.

Applies to the following strengths: 2 mg-125 mg

Usual Adult Dose for:

• Diarrhea - Acute

Usual Pediatric Dose for:

• Diarrhea - Acute

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Diarrhea - Acute

Initial dose: 2 tablets (2 mg-125 mg) orally with water after the first loose stool

Maintenance dose: 1 tablet after orally each subsequent loose stool; but no more than 4 tablets orally in 24 hours

Usual Pediatric Dose for Diarrhea - Acute

Initial dose: 1 tablet with water after the first loose stool for children 6 to 11 years

Maintenance dose: 1/2 tablet after each subsequent loose stool; but no more than 3 tablets in 24 hours for children 9 to 11 years and no more than 2 tablets in 24 hours for children 6 to 8 years

Consult a physician for children under 6 years.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

The safety of Imosec M in patients with liver disease has not been established. Because Imosec M may undergo hepatic metabolism, the manufacturer recommends that Imosec M-Simethicone (Imosec M) be used with caution. The manufacturer recommends all patients with liver dysfunction, on Imosec M therapy, be closely monitored for signs of CNS toxicity.

Dose Adjustments

Data not available

Precautions

Imosec M therapy should be stopped and a physician notified if symptoms get worse, diarrhea lasts for more than 48 hours, or abdominal swelling or bulging occurs.

Imosec M may impair the mental abilities necessary for potentially hazardous tasks such as driving a car or operating machinery.

Dialysis

Data not available

Other Comments

Maximum recommended dose for adults is 16 mg per day.

The duration of treatment for acute diarrhea with flatulence generally does not exceed 48 hours.

Therapy should be accompanied by fluid and electrolyte replacement as needed.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Imosec M

• Imosec M Side Effects
• During Pregnancy
• Drug Images
• Drug Interactions
• Drug class: antidiarrheals

Consumer resources

• Imosec M and Simethicone (Imosec M)

Other brands: Imodium Multi-Symptom Relief

Related treatment guides

• Diarrhea, Acute

See also:
What is the most important information I should know about Imosec M?

Pseudomembranous colitis caused by antibiotic use; acute diarrhea associated with organisms that penetrate intestinal wall (eg, toxigenic Escherichia coli, Salmonella, Shigella ); conditions in which constipation should be avoided; bloody diarrhea; fever; acute ulcerative colitis (potential for toxic megacolon).

Use Imosec M as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Imosec M by mouth with or without food.
• Drinking extra fluids is recommended while you have diarrhea. Check with your doctor if you have questions.
• If you miss a dose of Imosec M, take it as soon as you remember. Continue to take it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Imosec M.

Nonclinical data have shown that Imosec M is a P-glycoprotein substrate. Concomitant administration of Imosec M (16 mg single dose) with a 600 mg single dose of either quinidine, or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2- to 3- fold increase in Imosec M plasma levels. Due to the potential for enhanced central effects when Imosec M is coadministered with quinidine and with ritonavir, caution should be exercised when Imosec M is administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.

When a single 16-mg dose of Imosec M is coadministered with a 600 mg single dose of saquinavir, Imosec M decreased saquinavir exposure by 54%, which may be of clinical relevance due to reduction of therapeutic efficacy of saquinavir. The effect of saquinavir on Imosec M is of less clinical significance. Therefore, when Imosec M is given with saquinavir, the therapeutic efficacy of saquinavir should be closely monitored.

See also:
What are the possible side effects of Imosec M?

Applies to Imosec M / Simethicone (Imosec M): tablets

No COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur while taking Imosec M / Simethicone (Imosec M):

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); constipation; decreased urination; red, swollen, blistered, or peeling skin; stomach bloating, swelling, or pain.